Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Hence, the providers are more likely to adopt biosimilars as a 'reference product to biologics' possessing similar therapeutic properties
The US FDA took an initiative to develop new pathways for Insulin biosimilars. Our team at PharmaShots has…
